FDA drug alerts in endocrinology, including drug approvals, drug warnings, FDA medical device recalls, and FDA drug label ...

Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...

Teva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...

Bristol Myers Squibb's Opdivo has been approved in a subcutaneous injection formulation by the FDA, making treatment easier for patients and potentially adding years to the product's patent life.

Subcutaneous immunotherapy (SCIT) is a unique therapy for allergic disease because it provides symptomatic relief while modifying the allergic disease by targeting the underlying immunological ...

The FDA has approved label changes for once-monthly Sublocade, helping to reduce possible barriers to treatment initiation ...

Selarsdi is approved by the FDA in several presentations, including 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled ...

Switching from IV to subcutaneous infliximab maintenance therapy is associated with high treatment persistence and a stable ...

The following is a summary of “Patient preferences for long-acting HIV treatment: a preference heterogeneity assessment,” ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology arsenal.

Heading into 2025, the chief item on argenx’s agenda is the FDA’s April 10 target action date to decide on the approval of a ...